165 related articles for article (PubMed ID: 27221913)
1. Hepatocellular Carcinoma in a Tertiary Referral Hospital in Indonesia: Lack of Improvement of One-Year Survival Rates between 1998-1999 and 2013-2014.
Loho IM; Hasan I; Lesmana CR; Dewiasty E; Gani RA
Asian Pac J Cancer Prev; 2016; 17(4):2165-70. PubMed ID: 27221913
[TBL] [Abstract][Full Text] [Related]
2. Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort.
Sinn DH; Gwak GY; Cho J; Paik SW; Yoo BC
PLoS One; 2014; 9(11):e112184. PubMed ID: 25372403
[TBL] [Abstract][Full Text] [Related]
3. The Improvement in 1-Year Survival Rate of Patients with Hepatocellular Carcinoma BCLC Stage A and B after the Implementation of Comprehensive Management.
Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S
J Gastrointest Cancer; 2020 Sep; 51(3):829-835. PubMed ID: 31502104
[TBL] [Abstract][Full Text] [Related]
4. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.
Weinmann A; Koch S; Niederle IM; Schulze-Bergkamen H; König J; Hoppe-Lotichius M; Hansen T; Pitton MB; Düber C; Otto G; Schuchmann M; Galle PR; Wörns MA
J Clin Gastroenterol; 2014 Mar; 48(3):279-89. PubMed ID: 24045276
[TBL] [Abstract][Full Text] [Related]
5. Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective.
Li JW; Goh BG; Chang PE; Tan CK
World J Gastroenterol; 2017 Jun; 23(22):4054-4063. PubMed ID: 28652658
[TBL] [Abstract][Full Text] [Related]
6. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.
Costentin CE; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Letouzé E; Imbeaud S; Zucman-Rossi J; Audureau E; Roudot-Thoraval F; Nahon P;
Gastroenterology; 2018 Aug; 155(2):431-442.e10. PubMed ID: 29729258
[TBL] [Abstract][Full Text] [Related]
7. Postoperative Outcomes for Patients with Non-B Non-C Hepatocellular Carcinoma: A Subgroup Analysis of Patients with a History of Hepatitis B Infection.
Omichi K; Shindoh J; Yamamoto S; Matsuyama Y; Akamatsu N; Arita J; Kaneko J; Sakamoto Y; Hasegawa K; Kokudo N
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1034-40. PubMed ID: 26350363
[TBL] [Abstract][Full Text] [Related]
8. Independent Predictors of Mortality and Resource Utilization in Viral Hepatitis Related Hepatocellular Carcinoma.
Golabi P; Jeffers T; Younoszai Z; Otgonsuren M; Sayiner M; Mishra A; Venkatesan C; Younossi ZM
Ann Hepatol; 2017; 16(4):555-564. PubMed ID: 28611258
[TBL] [Abstract][Full Text] [Related]
9. Impact of viral hepatitis on outcomes after liver resection for hepatocellular carcinoma: results from a north american center.
Lee JJ; Kim PT; Fischer S; Fung S; Gallinger S; McGilvray I; Moulton CA; Wei AC; Greig PD; Cleary SP
Ann Surg Oncol; 2014 Aug; 21(8):2708-16. PubMed ID: 24806113
[TBL] [Abstract][Full Text] [Related]
10. Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015.
Kim NG; Nguyen PP; Dang H; Kumari R; Garcia G; Esquivel CO; Nguyen MH
Cancer; 2018 Jun; 124(12):2588-2598. PubMed ID: 29624631
[TBL] [Abstract][Full Text] [Related]
11. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
12. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma.
Jun TW; Yeh ML; Yang JD; Chen VL; Nguyen P; Giama NH; Huang CF; Hsing AW; Dai CY; Huang JF; Chuang WL; Roberts LR; Yu ML; Nguyen MH
Liver Int; 2018 May; 38(5):895-902. PubMed ID: 29045023
[TBL] [Abstract][Full Text] [Related]
13. Liver resection for hepatocellular carcinoma in patients with hematological malignancies.
Lin HC; Yang YS; Teng CJ; Shen CH; Jan YG; Cheng SB; Wu CC; Lin YL; Huang CC; P'eng FK
World J Surg Oncol; 2017 Nov; 15(1):194. PubMed ID: 29096656
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hepatocellular carcinoma in a tertiary Romanian center. Deviations from BCLC recommendations and influence on survival rate.
Radu P; Groza I; Iancu C; Al Hajjar N; Andreica V; Sparchez Z
J Gastrointestin Liver Dis; 2013 Sep; 22(3):291-7. PubMed ID: 24078986
[TBL] [Abstract][Full Text] [Related]
15. Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia.
Jasirwan COM; Hasan I; Sulaiman AS; Lesmana CRA; Kurniawan J; Kalista KF; Nababan SH; Gani RA
Curr Probl Cancer; 2020 Feb; 44(1):100480. PubMed ID: 31130257
[TBL] [Abstract][Full Text] [Related]
16. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of clinical characteristics of non-B non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma and prognosis in Uighur patients].
Zhang R; Zhou S; Xiao L; Zhang H; Tulahong A; Zhang Y; Wen H; Bao Y
Zhonghua Zhong Liu Za Zhi; 2015 Jul; 37(7):540-4. PubMed ID: 26463333
[TBL] [Abstract][Full Text] [Related]
18. Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.
Ikeda K; Kawamura Y; Kobayashi M; Kominami Y; Fujiyama S; Sezaki H; Hosaka T; Akuta N; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Dig Dis Sci; 2017 Oct; 62(10):2932-2942. PubMed ID: 28884320
[TBL] [Abstract][Full Text] [Related]
19. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival.
Ishikawa T; Higuchi K; Kubota T; Seki K; Honma T; Yoshida T; Kamimura T
Hepatogastroenterology; 2012; 59(114):529-32. PubMed ID: 22024226
[TBL] [Abstract][Full Text] [Related]
20. Differences in prognostic factors according to viral status in patients with hepatocellular carcinoma.
Akahoshi H; Taura N; Ichikawa T; Miyaaki H; Akiyama M; Miuma S; Ozawa E; Takeshita S; Muraoka T; Matsuzaki T; Ohtani M; Isomoto H; Matsumoto T; Takeshima F; Nakao K
Oncol Rep; 2010 May; 23(5):1317-23. PubMed ID: 20372846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
